When Dr. Yasmeen Rauf meets patients with glioblastoma, she knows the odds are brutal. About half of people diagnosed with this aggressive brain cancer live no more than 18 months, and roughly 70% do not survive five years. The standard treatment hasn't changed since 2005. But at the University of North Carolina at Chapel Hill, a wave of new research is offering real reason for hope.

At UNC Health, scientists are testing several experimental therapies that could fundamentally change how this cancer is treated. One trial, started in 2022, is exploring CAR-T cell therapy — a technique that takes immune cells from patients, reprograms them in a lab to recognize and attack tumor cells, then returns them to the body. Dr. Rauf, an assistant professor in UNC's neurology and neurosurgery departments, is leading this study with patients whose cancer didn't respond to earlier treatments.

Another large trial is testing IGV-001, an immunotherapy developed by the biotech company Imvax Inc. The study aims to enroll 93 newly diagnosed patients across multiple sites — and UNC Health is the only location in North Carolina and the entire South offering it. Fourteen satellite clinics throughout the state will help patients avoid traveling to Chapel Hill for weekly treatments. After tumor-removal surgery, patients receive small chambers containing either IGV-001 or a placebo, designed to spark a powerful immune attack against cancer cells. Dr. Soma Sengupta, vice chair of the neurology department, leads that study, working alongside Dr. Dominique Higgins and Dr. Carlos David.

A third approach comes from Northwest Biotherapeutics. A November 2022 study found their personalized immune therapy extended survival for many patients. Dr. Matt Ewend, a neurosurgery professor at UNC, ran the local trial site at the N.C. Basnight Cancer Hospital and co-authored the study report.

Meanwhile, researchers at the Eshelman School of Pharmacy have built something straight out of science fiction: a "brain slice" tool. Associate professor Shawn Hingtgen and research assistant professor Andrew Satterlee keep living tumor tissue alive outside the body so doctors can test different drugs and see which one works best — like a rehearsal before the real performance. Hingtgen's team is also studying specific receptors on cancer cells that drive tumor growth, using imaging to track how well treatments are working.

The depth of UNC's research matters. Glioblastoma has long been a stubborn enemy, but these trials represent different angles of attack — reprogramming the immune system, awakening the body's own defenses, and personalizing medicine for each patient. Researchers like Dr. Dominique Higgins are already connecting this work to surgical patients in real time, bringing lab discoveries directly to the bedside.

No breakthroughs are guaranteed, and patients still face grim statistics. But for the first time in years, the tools being developed at one university could shift those numbers — not with a single silver bullet, but with an arsenal of them.